CD28

CD28 是一种细胞表面糖蛋白受体,主要在活化的 T 细胞上表达,属于 Ig 超家族,可提供关键的共刺激信号。其配体 CD80 和 CD86 通常位于抗原呈递细胞表面,可结合 CD28 或 CTLA-4。CD28 与亲和力相对较高的 CD80 二聚体相互作用,与亲和力较低的 CD86 单体相互作用,与 T 细胞受体 (TCR) 信号一起介导 T 细胞共刺激。CD28 驱动关键的细胞内生化事件,包括独特的磷酸化和转录信号传导、代谢以及关键细胞因子、趋化因子和生存信号的产生,这些对于 T 细胞的长期扩增和分化至关重要。最重要的是,用可溶性 CD28 拮抗剂治疗小鼠可诱导抗原特异性耐受性,从而防止自身免疫性疾病的进展和器官移植排斥。

CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and provides a critical co-stimulatory signal. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. CD28 interacts with the CD80 dimer with relatively high affinity and the CD86 monomer with lower affinity, mediating T cell co-stimulation in conjunction with T cell receptor (TCR) signals. CD28 drives critical intracellular biochemical events including unique phosphorylation and transcriptional signaling, metabolism, and the production of key cytokines, chemokines, and survival signals that are essential for long-term expansion and differentiation of T cells. Most importantly, treatment of mice with a soluble CD28 antagonist induced antigen-specific tolerance that prevented the progression of autoimmune diseases and organ graft rejection.

共 2种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
Acazicolcept
ALPN-101

Azacicolcept (ALPN-101) 是一种具有抗炎活性的 Fc 融合蛋白,也是一种双重诱导型 T 细胞共刺激物 (ICOS)/CD28 拮抗剂。

2797026-97-0
Antagonist
99.27%
Acazicolcept
Reltecimod
AB-103

Reltecimod (AB-103) 是一种靶向 T 细胞特异性表面糖蛋白 CD28 (TP44) 的拮抗剂,通过靶向并减弱关键的 CD28/B7-2 共刺激通路来调节而非抑制炎症反应,对不同的细菌感染、细菌外毒素和内毒素以及电离辐射均具有良好的抗性作用,可用于研究坏死性软组织感染 (NSTIs)。

1447799-33-8
Antagonist
98.62%
Reltecimod

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础